None
Quote | Replimune Group Inc. (NASDAQ:REPL)
Last: | $10.25 |
---|---|
Change Percent: | 1.69% |
Open: | $9.87 |
Close: | $10.25 |
High: | $10.5 |
Low: | $9.76 |
Volume: | 507,969 |
Last Trade Date Time: | 07/24/2024 03:00:00 am |
News | Replimune Group Inc. (NASDAQ:REPL)
2024-07-16 11:50:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. With large-cap valuati...
2024-07-14 02:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Message Board Posts | Replimune Group Inc. (NASDAQ:REPL)
Subject | By | Source | When |
---|---|---|---|
ASCO Initial efficacy and safety of RP1 + nivolumab | jondoeuk | investorshub | 04/30/2023 5:31:31 PM |
It made headlines both sides of the pond. | jondoeuk | investorshub | 04/13/2023 10:58:14 PM |
(OT) Identification of a viral 5'leader that augments | jondoeuk | investorshub | 04/07/2023 12:02:26 AM |
More here https://www.evaluate.com/vantage/articles/news/trial-results/replimune | jondoeuk | investorshub | 03/19/2023 10:32:34 PM |
Link to webcast https://www.wsw.com/webcast/cc/repl3/register.aspx?conf=cc&page= | jondoeuk | investorshub | 12/06/2022 1:09:05 AM |
News, Short Squeeze, Breakout and More Instantly...
2024-07-14 02:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- Led by a life-sciences focused institutional investor, with participation from Redmile Group, RTW Investments, Boxer Capital and other institutional investors - - Financing follows strong primary analysis data from the RP1 IGNYTE clinical trial in anti-PD1 failed melanoma; BLA fi...
WOBURN, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Sushil Patel, Chief Executive Officer of Replimune, will present at the Gold...